NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Forecast, Price & News $5.88 +0.61 (+11.57%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$5.25▼$5.8850-Day Range$2.14▼$5.8852-Week Range$0.85▼$5.88Volume131,715 shsAverage Volume188,486 shsMarket Capitalization$48.04 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Soleno Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.1% Upside$8.00 Price TargetShort InterestHealthy1.25% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment1.19Based on 7 Articles This WeekInsider TradingAcquiring Shares$647,150 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.71) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector305th out of 1,980 stocksElectromedical Equipment Industry5th out of 46 stocks 3.5 Analyst's Opinion Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Soleno Therapeutics has a forecasted upside of 36.1% from its current price of $5.88.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.25% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 14.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.55. Previous Next 2.9 News and Social Media Coverage News SentimentSoleno Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Soleno Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for SLNO on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $647,150.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders23.70% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($1.71) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 18.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Soleno Therapeutics (NASDAQ:SLNO) StockSoleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.Read More Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Stock News HeadlinesMay 31, 2023 | americanbankingnews.comAnalyzing Soleno Therapeutics (NASDAQ:SLNO) and Nexalin Technology (NASDAQ:NXL)May 28, 2023 | americanbankingnews.comPerceptive Advisors Llc Buys 22,500 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockJune 2, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.May 28, 2023 | americanbankingnews.comPerceptive Advisors Llc Acquires 25,000 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockMay 25, 2023 | msn.comOppenheimer Reiterates Soleno Therapeutics (SLNO) Outperform RecommendationMay 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Soleno Therapeutics (SLNO) and Bioline RX Ltd Sponsored ADR (BLRX)May 25, 2023 | americanbankingnews.comPerceptive Advisors Llc Purchases 27,300 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockMay 24, 2023 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Major Shareholder Perceptive Advisors Llc Buys 25,200 SharesJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 8, 2023 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) versus Movano (NASDAQ:MOVE) Critical ContrastMay 3, 2023 | finance.yahoo.comSoleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi SyndromeApril 26, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn SituationMarch 28, 2023 | finance.yahoo.comSoleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease DaysMarch 28, 2023 | americanbankingnews.comOppenheimer Comments on Soleno Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:SLNO)March 27, 2023 | americanbankingnews.comOppenheimer Reaffirms Outperform Rating for Soleno Therapeutics (NASDAQ:SLNO)March 21, 2023 | finance.yahoo.comSoleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial ResultsMarch 18, 2023 | seekingalpha.comSLNO Soleno Therapeutics, Inc.March 16, 2023 | finance.yahoo.comSoleno Therapeutics, Inc.'s (NASDAQ:SLNO) Shift From Loss To ProfitMarch 7, 2023 | finance.yahoo.comSoleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 9, 2023 | finance.yahoo.com7 Top Short-Squeeze Candidates to Watch in FebruaryJanuary 30, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)January 29, 2023 | reuters.comSLNO.OQ - | Stock Price & Latest News | ReutersJanuary 26, 2023 | finance.yahoo.comSoleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi SyndromeDecember 20, 2022 | msn.comPeering Into Soleno Therapeutics's Recent Short InterestDecember 19, 2022 | marketwatch.comSoleno Therapeutics Shares Double After Financing CommitmentDecember 19, 2022 | markets.businessinsider.comWhy Is Soleno Therapeutics (SLNO) Stock Up 130% Today?December 19, 2022 | marketwatch.comThinking about buying stock in Mullen Automotive, Soleno Therapeutics, Agrify, AMC Entertainment, or Amyris?See More Headlines SLNO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNO Company Calendar Last Earnings3/21/2023Today6/01/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+36.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.1196) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-220.22% Return on Assets-92.97% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book18.38Miscellaneous Outstanding Shares8,170,000Free Float6,233,000Market Cap$48.04 million OptionableNot Optionable Beta0.22 Key ExecutivesAnish BhatnagarPresident, Chief Executive & Operating OfficerJames H. MackanessChief Financial OfficerKristen YenVice President-Clinical OperationsMichael WoloschakVice President-Clinical DevelopmentHarish RavivarapuVice President-Technical OperationsKey CompetitorsMovanoNASDAQ:MOVEPrecision OpticsNASDAQ:POCIelectroCoreNASDAQ:ECORVivani MedicalNASDAQ:VANIHyperfineNASDAQ:HYPRView All CompetitorsInsiders & InstitutionsPerceptive Advisors LlcBought 7,500 shares on 6/1/2023Total: $41,925.00 ($5.59/share)Perceptive Advisors LlcBought 17,500 shares on 5/30/2023Total: $93,450.00 ($5.34/share)Perceptive Advisors LlcBought 22,500 shares on 5/26/2023Total: $118,575.00 ($5.27/share)Perceptive Advisors LlcBought 25,000 shares on 5/24/2023Total: $137,000.00 ($5.48/share)Perceptive Advisors LlcBought 27,300 shares on 5/22/2023Total: $139,776.00 ($5.12/share)View All Insider TransactionsView All Institutional Transactions SLNO Stock - Frequently Asked Questions Should I buy or sell Soleno Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SLNO shares. View SLNO analyst ratings or view top-rated stocks. What is Soleno Therapeutics' stock price forecast for 2023? 1 Wall Street analysts have issued 12 month target prices for Soleno Therapeutics' shares. Their SLNO share price forecasts range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View analysts price targets for SLNO or view top-rated stocks among Wall Street analysts. How have SLNO shares performed in 2023? Soleno Therapeutics' stock was trading at $1.98 on January 1st, 2023. Since then, SLNO shares have increased by 197.0% and is now trading at $5.88. View the best growth stocks for 2023 here. When is Soleno Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our SLNO earnings forecast. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its earnings results on Tuesday, March, 21st. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.76) by $0.18. When did Soleno Therapeutics' stock split? Soleno Therapeutics's stock reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD). What is Soleno Therapeutics' stock symbol? Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO." Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Carlyle Group Inc. (14.71%), Renaissance Technologies LLC (0.94%), JPMorgan Chase & Co. (0.86%) and Dimensional Fund Advisors LP (0.37%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Perceptive Advisors Llc and William G Harris. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Soleno Therapeutics' stock price today? One share of SLNO stock can currently be purchased for approximately $5.88. How much money does Soleno Therapeutics make? Soleno Therapeutics (NASDAQ:SLNO) has a market capitalization of $48.04 million. The company earns $-24,070,000.00 in net income (profit) each year or ($3.1196) on an earnings per share basis. How can I contact Soleno Therapeutics? Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The official website for the company is www.soleno.life. The company can be reached via phone at (650) 213-8444, via email at ir@soleno.life, or via fax at 650-213-8383. This page (NASDAQ:SLNO) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.